A Study of TAS-120 in Patients With Metastatic Breast Cancer

Stopped The Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.

Conditions

• Metastatic Breast Cancer
• FGFR 1 High Amplification
• FGFR2 Amplification

Interventions

• DRUG: Futibatinib
• DRUG: Futibatinib plus Fulvestrant

Sponsor

Taiho Oncology, Inc.